Travere Therapeutics is a biopharmaceutical company founded in 2011, focused on developing therapies for people living with rare diseases. The company's mission is to identify, develop, and deliver treatments for conditions with limited existing options, working closely with patient advocacy groups and healthcare professionals.
Travere has an FDA-approved therapy for IgA nephropathy. Its pipeline includes investigational programs targeting focal segmental glomerulosclerosis (FSGS) and classical homocystinuria (HCU).
The company employs more than 450 people and operates with values of courage, community, and collaboration. It describes its culture as patient-inspired and 'in rare for life.'
